A Comparison of Reboxetine and Amitryptilline in the Treatment of Fibromyalgia Syndrome with Co-morbid Depressive Symptoms: An Open-label Preliminary Study

Konuk, Numan; Ortancil, Ozgur; Bostanci, Bora; Kiran, Sibel; Sapmaz, Perihan

doi:10.1080/10177833.2010.11790631

A Comparison of Reboxetine and Amitryptilline in the Treatment of Fibromyalgia Syndrome with Co-morbid Depressive Symptoms: An Open-label Preliminary Study

Copy For Citation

Konuk N., Ortancil O., Bostanci B., Kiran S., Sapmaz P.

KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.20, no.1, pp.29-37, 2010 (SCI-Expanded)

Publication Type: Article / Article
Volume: 20 Issue: 1
Publication Date: 2010
Doi Number: 10.1080/10177833.2010.11790631
Journal Name: KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
Page Numbers: pp.29-37
Istanbul University Affiliated: Yes

Abstract

Objective: Fibromyalgia (FM) is a chronic debilitating disorder that results in millions of dollars of heathcare costs and lost wages each year worldwide. It is a significant public health concern and new treatments are needed. In this study, we aimed to compare the effectiveness of a widely used tricyclic antidepressant for FM (amitryptylline) and one that has not yet been widely used (reboxetine) for FM in a within-subject pre-posttreatment design. Additionally, since noradrenaline (NA) is thought to play a relevant role in the antinociceptive mechanisms, we also aimed to examine the effectiveness of reboxetine as a selective NA reuptake inhibitor (NARI) in patients with fibromialgia.